DTA Releases & Statements

DTA Announces 2021 Board of Directors and Work Group Leaders

January 28, 2021

Thursday, January 28 – Arlington, VA – The Digital Therapeutics Alliance (DTA) is pleased to welcome member company leaders to the DTA Board of Directors and Work Group leadership. In our effort to transform global healthcare by advancing digital therapeutics, we are grateful to work with each of the following individuals.

Board of Directors
The DTA Board of Directors provides critical guidance related to the strategy and direction of the organization. The newest member of DTA’s Board is Scott Kollins, Ph.D, Professor within the Department of Psychiatry and Behavioral Science at the Duke University School of Medicine, and Co-Lead Digital Health Solutions with Duke Clinical Research Institute.

DTA’s 2021 Executive Committee includes: Debra Reisenthel (Chair), Eddie Martucci (Vice-Chair), Pierre Leurent (Secretary), and Scott Kollins (Treasurer).

Board Chair, Debra Reisenthel shares: “I am honored to assume the role of Board Chair of DTA during this exciting time for the Alliance. We accomplished much on behalf of our members in 2020 and we look forward to continuing this momentum in 2021. Our focus this year will be on the following global initiatives: expanding payor reimbursement opportunities, educating healthcare providers on the efficacy and value of digital therapeutics, and building confidence in the application of digital therapeutics within the healthcare ecosystem.”

DTA Member Work Groups
In line with DTA’s growing global work, this year we are proud to launch three regionally-based work groups led by industry experts:

As DTA leads the digital therapeutic industry in 2021, our collective efforts will be instrumental in providing patients and caregivers, clinicians, policy and healthcare decision makers with reliable resources to meaningfully integrate DTx products into practice and transform global healthcare.

About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more please visit: www.dtxalliance.org.


Copyright © 2024 Digital Therapeutics Alliance™